Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Will Highlight New Data on Its MS Program at 7th joint ECTRIMS-ACTRIMS Meeting


TEVA logoTeva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced that new data on its multiple sclerosis (MS) program, including COPAXONE® (glatiramer acetate injection), a product for relapsing forms of MS, and laquinimod, an investigational MS therapy, will be highlighted in 11 presentations at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) in Paris, October 25-28, 2017.

“New data from Teva’s MS program further contributes to the scientific understanding of treating a complex disease like MS,” said Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific Officer at Teva. “We look forward to showcasing our findings at this year’s joint ECTRIMS-ACTRIMS meeting.”

Shares of Teva Pharmaceutical are currently trading at $14.73, up $0.11 or 0.82%. TEVA has a 1-year high of $44.42 and a 1-year low of $14.30. The stock’s 50-day moving average is $16.61 and its 200-day moving average is $25.71.

On the ratings front, Teva stock has been the subject of a number of recent research reports. In a report issued on October 6, Piper Jaffray analyst David Amsellem reiterated a Hold rating on TEVA, with a price target of $23, which implies an upside of 57% from current levels. Separately, on October 5, Morgan Stanley’s David Risinger maintained a Sell rating on the stock and has a price target of $15.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, David Amsellem and David Risinger have a yearly average loss of -0.7% and -9.6% respectively. Amsellem has a success rate of 49% and is ranked #3720 out of 4695 analysts, while Risinger has a success rate of 42% and is ranked #4511.

Sentiment on the street is mostly neutral on TEVA stock. Out of 17 analysts who cover the stock, 12 suggest a Hold rating , 3 suggest a Sell and 2 recommend to Buy the stock. The 12-month average price target assigned to the stock is $20.88, which implies an upside of 43% from current levels.

Teva is a global pharmaceutical company, which provides patient-centric healthcare solutions. It operates through two segments: Generic Medicines and Specialty Medicines. The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment engages in the provision of core therapeutic areas of central nervous system medicines.

 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts